Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents
儿童和青少年焦虑症的脑标志物和 SSRI 治疗
基本信息
- 批准号:8240081
- 负责人:
- 金额:$ 46.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdolescenceAdolescentAdultAffectAftercareAgeAmygdaloid structureAngerAnxietyAnxiety DisordersBiological MarkersBrainCaringChildChildhoodClinicalClinical TreatmentClinical TrialsComorbidityControlled Clinical TrialsCouplingCuesDataDevelopmentExhibitsFaceFrightFunctional Magnetic Resonance ImagingFunctional disorderGoalsIndividualIndividual DifferencesInterventionKnowledgeLifeMediatingMental DepressionMental disordersModalityMorbidity - disease rateNeurobiologyOutcomePatientsPatternPharmaceutical PreparationsPilot ProjectsPlacebo ControlPlacebosPlayPrefrontal CortexProbabilityProcessPublishingRandomizedResearchRiskRoleSelective Serotonin Reuptake InhibitorSeparation AnxietySertralineSeveritiesSignal TransductionSocial PhobiaSpeedSubstance abuse problemSuicideSymptomsTherapeutic EffectTimeWorkYouthaffective neurosciencealternative treatmentbaseclinical carecommon treatmentcomparison groupdepressive symptomsdesigneffective therapyinnovationneural circuitneuromechanismnovelpublic health relevancerelating to nervous systemresponsesuccesstreatment responsetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Anxiety disorders, highly prevalent and disabling conditions in children and adolescents, rarely remit and increase the risk of subsequent depression, anxiety, substance abuse, and suicide in adulthood. Available treatments when effective can reduce morbidity, but often yield only modest success. One important strategy would be to guide individual patients towards treatments that have the highest likelihood of treatment success. Although SSRIs are widely used for pediatric anxiety disorders, little is known about how these medications exert their therapeutic effects. This knowledge gap precludes the development of biologically-based, hypothesis-driven breakthroughs to guide patients towards individually-tailored, optimal treatment strategies. This proposal seeks to discover neural markers that can be used to understand how SSRIs exerts their effect and to inform treatment decisions. Published work and pilot studies from the PIs indicate that the neural circuitry (particularly amygdala- ventral prefrontal cortex [vPFC] circuitry) that mediates fear responding is relevant to the pathophysiology of anxiety disorders and may be related to clinical treatment response. In the context of a randomized, placebo-controlled clinical trial of the SSRI sertraline, a widely-used first-line treatment with a variable response rate (pooled estimate of 63%; range: 55-91%) based on controlled clinical trials, this study will perform pre- and post-treatment functional MRI (fMRI) of amygdala and amygdala-vPFC function in children and adolescents (age range: 7-19 years) with anxiety disorders (AD) and healthy comparison (HC) youths. The Aims are: 1) Compare amygdala reactivity and amygdala-ventral prefrontal cortex functional connectivity ('coupling') to signals of threat between children and adolescents with anxiety disorders (AD) and matched healthy control (HC) subjects prior to treatment; 2) Compare the change (pre- treatment vs. post-treatment) in amygdala reactivity and amygdala-vPFC functional connectivity (coupling) between AD youths treated with the SSRI sertraline and those treated with placebo (PBO); 3) Characterize the relationship between pre-treatment amygdala-vPFC functional connectivity (and amygdala reactivity) and subsequent sertraline treatment response in AD youths; and 4) Examine the effects of development on amygdala reactivity and amygdala-vPFC functional connectivity in relation to AD, treatment change, and predictor of treatment response. This approach is innovative as no study has examined the relationship between brain function on treatment response in children and adolescents with anxiety disorders in a placebo- controlled design. The expected outcome of this work will be to help identify the effects of SSRI treatment on brain function and the brain mechanisms that mediate individual differences SSRI treatment response. The broad goal is to help to guide young patients towards treatments with higher likelihood of success, minimize trial-and-error prescribing and speed delivery of effective care to patients. This work will also elucidate anxiety- related brain targets for novel interventions in children and adolescents.
PUBLIC HEALTH RELEVANCE: Anxiety disorders are highly prevalent, disabling, difficult-to-treat mental disorders that occur in children and adolescence; they can persist through life and increase the risk of subsequent depression, substance abuse, and suicide. Effective, and well-targeted interventions initiated early in the course of anxiety disorders has the potential to alleviate the burden, co-morbidity, and suffering associated with the illness. The primary goal of this research is to identify the effects of medication treatment on brain function and the brain markers of treatment response in order to save young patients costly and lengthy trials of medications that are unlikely to be effective and guide them to towards alternative treatment modalities that have a greater probability of success and/or less risk.
描述(由申请人提供):焦虑症是儿童和青少年中非常普遍的致残性疾病,很少缓解,并且会增加成年后抑郁、焦虑、药物滥用和自杀的风险。有效的可用治疗方法可以降低发病率,但通常只能取得有限的成功。一项重要的策略是指导个体患者接受最有可能成功的治疗。尽管 SSRI 广泛用于治疗儿童焦虑症,但人们对这些药物如何发挥治疗作用知之甚少。这种知识差距阻碍了基于生物学、假设驱动的突破的发展,无法指导患者采取个性化的最佳治疗策略。该提案旨在发现可用于了解 SSRIs 如何发挥作用并为治疗决策提供信息的神经标记。 PI 已发表的工作和初步研究表明,介导恐惧反应的神经回路(特别是杏仁核腹侧前额皮质 [vPFC] 回路)与焦虑症的病理生理学相关,并且可能与临床治疗反应相关。 SSRI 舍曲林是一种广泛使用的一线治疗药物,基于对照临床试验,反应率可变(汇总估计为 63%;范围:55-91%),在一项随机、安慰剂对照临床试验的背景下,本研究将对儿童和儿童的杏仁核和杏仁核-vPFC 功能进行治疗前和治疗后功能性 MRI (fMRI)。 患有焦虑症(AD)的青少年(年龄范围:7-19岁)和健康对照(HC)青少年。目标是: 1) 在治疗前将杏仁核反应性和杏仁核-腹侧前额皮质功能连接(“耦合”)与患有焦虑症(AD)的儿童和青少年以及匹配的健康对照(HC)受试者之间的威胁信号进行比较; 2) 比较接受 SSRI 舍曲林治疗的 AD 青少年和接受安慰剂 (PBO) 治疗的 AD 青少年杏仁核反应性和杏仁核-vPFC 功能连接(耦合)的变化(治疗前与治疗后); 3) 描述 AD 青少年治疗前杏仁核-vPFC 功能连接(和杏仁核反应性)与随后舍曲林治疗反应之间的关系; 4) 检查发育对杏仁核反应性和杏仁核-vPFC 功能连接与 AD、治疗变化和治疗反应预测因子的影响。这种方法具有创新性,因为还没有研究在安慰剂对照设计中检验患有焦虑症的儿童和青少年的大脑功能与治疗反应之间的关系。这项工作的预期结果将有助于确定 SSRI 治疗对大脑功能的影响以及介导 SSRI 治疗反应个体差异的大脑机制。总体目标是帮助指导年轻患者接受更有可能成功的治疗,最大限度地减少处方试错并加快为患者提供有效的护理。这项工作还将阐明与焦虑相关的大脑目标,以用于儿童和青少年的新干预措施。
公共卫生相关性:焦虑症是儿童和青少年中非常普遍、致残且难以治疗的精神障碍;它们可能会持续一生,并增加随后抑郁、药物滥用和自杀的风险。在焦虑症病程早期开始有效且有针对性的干预措施有可能减轻与疾病相关的负担、共病和痛苦。这项研究的主要目标是确定药物治疗对大脑功能的影响以及治疗反应的大脑标志物,以便为年轻患者节省昂贵且漫长的不太可能有效的药物试验,并指导他们采用成功概率更大和/或风险更低的替代治疗方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Stephen Monk其他文献
Christopher Stephen Monk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Stephen Monk', 18)}}的其他基金
Effects of poverty on affective development: A multi-level, longitudinal study
贫困对情感发展的影响:多层次、纵向研究
- 批准号:
9075688 - 财政年份:2015
- 资助金额:
$ 46.01万 - 项目类别:
Effects of poverty on affective development: A multi-level, longitudinal study
贫困对情感发展的影响:多层次、纵向研究
- 批准号:
8904276 - 财政年份:2014
- 资助金额:
$ 46.01万 - 项目类别:
Effects of poverty on affective development: A multi-level, longitudinal study
贫困对情感发展的影响:多层次、纵向研究
- 批准号:
8690209 - 财政年份:2014
- 资助金额:
$ 46.01万 - 项目类别:
Effects of poverty on affective development: A multi-level, longitudinal study
贫困对情感发展的影响:多层次、纵向研究
- 批准号:
9064843 - 财政年份:2014
- 资助金额:
$ 46.01万 - 项目类别:
Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents
儿童和青少年焦虑症的脑标志物和 SSRI 治疗
- 批准号:
7991966 - 财政年份:2010
- 资助金额:
$ 46.01万 - 项目类别:
Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents
儿童和青少年焦虑症的脑标志物和 SSRI 治疗
- 批准号:
8433431 - 财政年份:2010
- 资助金额:
$ 46.01万 - 项目类别:
Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents
儿童和青少年焦虑症的脑标志物和 SSRI 治疗
- 批准号:
8102062 - 财政年份:2010
- 资助金额:
$ 46.01万 - 项目类别:
1/2 Development of a Screening Interview for Research Studies of ASD
1/2 开发 ASD 研究筛选访谈
- 批准号:
7940793 - 财政年份:2009
- 资助金额:
$ 46.01万 - 项目类别:
Development of a Brief Screener for Research in Autism Spectrum Disorders
开发用于自闭症谱系障碍研究的简短筛选器
- 批准号:
7940917 - 财政年份:2009
- 资助金额:
$ 46.01万 - 项目类别:
Adolescent Social Phobia and Neurophysiological Function
青少年社交恐惧症与神经生理功能
- 批准号:
6617116 - 财政年份:2005
- 资助金额:
$ 46.01万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
- 批准号:
10756652 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
- 批准号:
10730872 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 46.01万 - 项目类别: